First National Trust Co Has $4.02 Million Stock Position in Pfizer Inc. $PFE

First National Trust Co lifted its stake in Pfizer Inc. (NYSE:PFE) by 0.4% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 165,789 shares of the biopharmaceutical company’s stock after acquiring an additional 703 shares during the period. First National Trust Co’s holdings in Pfizer were worth $4,019,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also modified their holdings of the company. Capital Advisors Inc. OK grew its stake in shares of Pfizer by 1.2% in the first quarter. Capital Advisors Inc. OK now owns 1,413,472 shares of the biopharmaceutical company’s stock worth $35,817,000 after acquiring an additional 17,032 shares during the last quarter. CHURCHILL MANAGEMENT Corp acquired a new stake in shares of Pfizer in the first quarter worth $8,283,000. Westbourne Investments Inc. bought a new position in Pfizer in the first quarter worth $2,411,000. Bourne Lent Asset Management Inc. lifted its position in Pfizer by 90.8% in the second quarter. Bourne Lent Asset Management Inc. now owns 38,255 shares of the biopharmaceutical company’s stock worth $927,000 after purchasing an additional 18,200 shares during the period. Finally, Strs Ohio bought a new position in Pfizer in the first quarter worth $49,968,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Analysts Set New Price Targets

Several research analysts recently commented on PFE shares. Citigroup raised their target price on Pfizer from $25.00 to $26.00 and gave the stock a “neutral” rating in a research report on Wednesday, August 6th. Bank of America raised their target price on Pfizer from $28.00 to $30.00 and gave the stock a “neutral” rating in a research report on Friday, October 3rd. UBS Group reaffirmed a “neutral” rating and issued a $28.00 target price on shares of Pfizer in a research report on Wednesday, October 1st. Morgan Stanley reduced their target price on Pfizer from $33.00 to $32.00 and set an “equal weight” rating for the company in a research report on Friday, October 10th. Finally, Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Pfizer in a research report on Wednesday, October 8th. Two analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, eleven have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Pfizer presently has a consensus rating of “Hold” and an average target price of $28.13.

Pfizer Stock Down 0.0%

Shares of NYSE PFE opened at $24.76 on Tuesday. The stock has a market cap of $140.75 billion, a PE ratio of 13.17, a PEG ratio of 0.82 and a beta of 0.55. The business has a fifty day moving average of $24.86 and a two-hundred day moving average of $24.21. Pfizer Inc. has a 52-week low of $20.92 and a 52-week high of $29.17. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.85 and a current ratio of 1.16.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.58 by $0.20. The company had revenue of $14.65 billion during the quarter, compared to analysts’ expectations of $13.43 billion. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The business’s revenue was up 10.3% on a year-over-year basis. During the same period last year, the business earned $0.60 earnings per share. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. As a group, equities research analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Monday, December 1st. Stockholders of record on Friday, November 7th will be paid a $0.43 dividend. The ex-dividend date is Friday, November 7th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.9%. Pfizer’s dividend payout ratio (DPR) is 91.49%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.